Sign up to save your podcasts
Or
Share Clot Fighter May Save CoVid19 Victims
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Clot Fighter May Save CoVid19 Victims
Vidcast: https://youtu.be/98zOq9ZpG9M
TPA, the clot busting tissue plasminogen activator that rescues heart attack and stroke patients, may help ventilator-dependent CoVid19 patients in respiratory failure. Researchers at MIT, Harvard teaching hospitals, and the University of Colorado believe that TPA can prevent extensive blood clotting that exacerbates CoVid19 patients’ respiratory failure.
Clinicians on the front lines of the coronavirus battle in New York and Europe report that infected patients clot too easily and have damaging clots not only in their lungs but also in their hearts and kidneys as part of multi-organ failure.
A federally-funded clinical trial of TPA will deliver the drug intravenously and via direct airway instillation. Genentech is donating the drug.
Hunter B. Moore, Christopher D. Barrett, Ernest E. Moore, Robert C. McIntyre, Peter K. Moore, Daniel S. Talmor, Frederick A. Moore, Michael B. Yaffe. Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)? Journal of Trauma and Acute Care Surgery, 2020; 1 DOI: 10.1097/TA.0000000000002694
#covid19 #coronavirus #tpa #respiratoryfailure #clotting
View all episodes
By Howard G. Smith MD, AM
Vidcast: https://youtu.be/98zOq9ZpG9M
TPA, the clot busting tissue plasminogen activator that rescues heart attack and stroke patients, may help ventilator-dependent CoVid19 patients in respiratory failure. Researchers at MIT, Harvard teaching hospitals, and the University of Colorado believe that TPA can prevent extensive blood clotting that exacerbates CoVid19 patients’ respiratory failure.
Clinicians on the front lines of the coronavirus battle in New York and Europe report that infected patients clot too easily and have damaging clots not only in their lungs but also in their hearts and kidneys as part of multi-organ failure.
A federally-funded clinical trial of TPA will deliver the drug intravenously and via direct airway instillation. Genentech is donating the drug.
Hunter B. Moore, Christopher D. Barrett, Ernest E. Moore, Robert C. McIntyre, Peter K. Moore, Daniel S. Talmor, Frederick A. Moore, Michael B. Yaffe. Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)? Journal of Trauma and Acute Care Surgery, 2020; 1 DOI: 10.1097/TA.0000000000002694
#covid19 #coronavirus #tpa #respiratoryfailure #clotting